Association Between Uric Acid / High Density Lipoprotein Ratio and Monocyte / High Density Lipoprotein Ratio with Diabetic Complications
NCT ID: NCT06754813
Last Updated: 2025-01-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
90 participants
OBSERVATIONAL
2025-01-01
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relation Between Serum Uric Acid and Metabolic Syndrome in Type 2 DM
NCT04575389
Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients
NCT05602532
Neutrophil-lymphocyte and Platelet-lymphocyte Ratios and Their Relations to Vascular Comlications and Glycemic Control in Patients With Type 2 Diabetes Attending The Diabetes Center of Assiut University Hospitals
NCT06073756
Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients
NCT01282060
Association of Triglyceride Glucose Index and HOMA IR as Predictors of Vascular Complications of DM Type 2
NCT05695651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Uric acid is the final enzymatic product of purine nucleoside and free base degradation. Elevated levels of serum uric acid (SUA) are widely recognized as a risk factor for macrovascular and microvascular complications. Hyperuricemia is particularly common in patients with hyperlipidemia.
It has been established that SUA levels are proportional to triglyceride (TG), total cholesterol (TC), and low-density lipoprotein (LDL) levels. SUA promotes the oxidation of LDL, which is considered to be a key event in atherosclerotic plaque formation. The findings of several epidemiological studies have thus provided evidence to indicate a clear independent association between elevated SUA levels and an increased incidence of atherosclerotic disease or mortality Decreased serum levels of High-density lipoprotein cholesterol (HDL-c) are proposed to be related to worse metabolic status and reduced HDL-c is even a marker of metabolic syndrome.
A combination of these two metabolic parameters uric acid to HDL-c ratio (UHR) which is a more useful predictor of metabolic deterioration High-density lipoprotein- cholesterol acts by reducing proinflammatory responses triggered by monocytes, effectively restricting monocyte proliferation, activation and migration, and plays a role in the anti-oxidant mechanism. In contrast, reduced levels of HDL-c in the blood stream imply a worsening metabolic profile and are a component of the metabolic syndrome Uric acid can cause atherosclerosis and insulin resistance by reducing nitric oxide production, promoting vascular smooth muscle proliferation, and resulting in endothelial dysfunction. Additionally, low levels of HDL-c play a role in the development of metabolic syndrome and insulin resistance.
More recently, the uric acid-to-HDL-c ratio (UHR) has been identified as a marker that increases in inflammatory conditions . Monocytes and macrophages play crucial roles in damage to pancreatic islet cells, islet inflammation and impaired insulin signaling in T2DM. The monocyte/ HDL-c ratio (MHR) has been proposed as an indicator of ongoing low-grade metabolic inflammation and has been suggested studies to be used as a marker for cardiovascular disease and chronic kidney disease .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group 1
Diabetic patients without any macrovascular and microvascular Complications.
No interventions assigned to this group
group 2
Diabetic patients with macrovascular (stroke, coronary heart disease, Peripheral artery disease) and microvascular (DN and DR) complications
No interventions assigned to this group
group 3
Apparent healthy subjects as control group.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* age more than 18 years old
* both sex
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mennat Allah Gamal Abdelnaser
resident doctor at Assiut University hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-S42. doi: 10.2337/dc24-S002.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HDL Uric UHR monocyte MHR DM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.